Advanced search
Publication Cover
Journal of Dermatological Treatment Volume 33, 2022 - Issue 3
Submit an article Journal homepage
2,662
Views
6
CrossRef citations to date
0
Altmetric
Articles

Clinical implications and predictive values of early PASI responses to tildrakizumab in patients with moderate-to-severe plaque psoriasis

Steven R. Feldmana Wake Forest School of Medicine, Winston-Salem, NC, USAView further author information
,
Joseph F. Merolab Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USAView further author information
,
David M. Pariserc Eastern Virginia Medical School, Virginia Clinical Research, Inc, Norfolk, VA, USAView further author information
,
Jingchuan Zhangd Sun Pharmaceutical Industries Inc., Princeton, NJ, USAView further author information
,
Yang Zhaod Sun Pharmaceutical Industries Inc., Princeton, NJ, USAView further author information
,
Alan M. Mendelsohnd Sun Pharmaceutical Industries Inc., Princeton, NJ, USACorrespondence[email protected]
View further author information
&
Alice B. Gottliebe Icahn School of Medicine at Mount Sinai, New York, NY, USAView further author information
 show all
Pages 1670-1675 | Received 16 Feb 2021, Accepted 26 Feb 2021, Published online: 18 Mar 2021

References

  • Menter A, Cordoro KM, Davis DMR, et al. Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients. J Am Acad Dermatol. 2020;82(1):161–201.
  • Pinter A, Gerdes S, Papavassilis C, et al. Characterization of responder groups to secukinumab treatment in moderate to severe plaque psoriasis. J Dermatolog Treat. 2020;31(8):769–775.
  • Zhu B, Edson-Heredia E, Cameron GS, et al. Early clinical response as a predictor of subsequent response to ixekizumab treatment: results from a phase II study of patients with moderate-to-severe plaque psoriasis. Br J Dermatol. 2013;169(6):1337–1341.
  • Tan H, Valdez H, Griffins CE, et al. Early clinical response to tofacitinib treatment as a predictor of subsequent efficacy: results from two phase 3 studies of patients with moderate-to-severe plaque psoriasis. J Dermatolog Treat. 2017;28(1):3–7.
  • van der Heijde D, Deodhar A, Fleischmann R, et al. Early disease activity or clinical response as predictors of long-term outcomes with certolizumab pegol in axial spondyloarthritis or psoriatic arthritis. Arthritis Care Res (Hoboken). 2017;69(7):1030–1039.
  • Reich K, Papp KA, Blauvelt A, et al. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials. Lancet. 2017;390(10091):276–288.
  • Blauvelt A, Sofen H, Papp K, et al. Tildrakizumab efficacy and impact on quality of life up to 52 weeks in patients with moderate-to-severe psoriasis: a pooled analysis of two randomized controlled trials. J Eur Acad Dermatol Venereol. 2019;33(12):2305–2312.
  • Reich K, Warren RB, Iversen L, et al. Long-term efficacy and safety of tildrakizumab for moderate-to-severe psoriasis: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2) through 148 weeks. Br J Dermatol. 2020;182(3):605–617.
  • Puig L. PASI90 response: the new standard in therapeutic efficacy for psoriasis. J Eur Acad Dermatol Venereol. 2015;29(4):645–648.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.